

## TO THE EDITOR:

## Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

Luzalba Sanoja-Flores,<sup>1,5</sup> Juan Flores-Montero,<sup>1,5</sup> Noemi Puig,<sup>1,4,6</sup> Teresa Contreras-Sanfeliciano,<sup>7</sup> Roberia Pontes,<sup>8</sup> Alba Corral-Mateos,<sup>1,5</sup> Omar García-Sánchez,<sup>1,4,6</sup> María Díez-Campelo,<sup>1,4,6</sup> Roberto José Pessoa de Magalhães,<sup>9</sup> Luis García-Martín,<sup>10</sup> José María Alonso-Alonso,<sup>11</sup> Aranzazú García-Mateo,<sup>12</sup> Carlos Aguilar-Franco,<sup>13</sup> Jorge Labrador,<sup>14</sup> Abelardo Barez-García,<sup>15</sup> Angelo Maiolino,<sup>9</sup> Bruno Paiva,<sup>4,16</sup> Jesús San Miguel,<sup>4,16</sup> Elaine Sobral da Costa,<sup>8</sup> Marcos González,<sup>1,4,6</sup> María Victoria Mateos,<sup>1,4,6</sup> Brian Durie,<sup>17</sup> Jacques J. M. van Dongen,<sup>18</sup> and Alberto Orfao,<sup>1,5</sup> on behalf of the EuroFlow Consortium

<sup>1</sup>Cancer Research Center–Instituto de Biología Celular y Molecular del Cáncer (IBMCC) of the Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain; <sup>2</sup>Cytometry Service (NUCLEUS) and <sup>3</sup>Department of Medicine, University of Salamanca, Salamanca, Spain; <sup>4</sup>Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto Carlos III, Madrid, Spain; <sup>5</sup>Instituto de Investigación Biosanitaria (IBSAL), Salamanca, Spain; <sup>6</sup>Department of Hematology and <sup>7</sup>Department of Biochemistry, University Hospital of Salamanca, Salamanca, Spain; <sup>8</sup>Department of Pediatrics, Institute of Pediatrics and Puericulture Martagão Gesteira (IPPMG) and <sup>9</sup>University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; <sup>10</sup>Department of Hematology, Hospital of Zamora, Zamora, Spain; <sup>11</sup>Department of Hematology, Hospital of Palencia, Palencia, Spain; <sup>12</sup>Department of Hematology, Hospital of Segovia, Segovia, Spain; <sup>13</sup>Department of Hematology, Hospital of Soria, Soria, Spain; <sup>14</sup>Department of Hematology, Hospital of Burgos, Burgos, Spain; <sup>15</sup>Department of Hematology, Hospital of Ávila, Ávila, Spain; <sup>16</sup>Clinica Universidad de Navarra, Applied Medical Research Center (CIMA), IDISNA, Pamplona, Spain; <sup>17</sup>Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA; and <sup>18</sup>Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

In recent years, detection of circulating tumor plasma cells (CTPC), tumor cell–derived deoxyribonucleic acid (DNA), RNA, or protein markers in blood has gained interest for disease monitoring in multiple myeloma (MM).<sup>1,2</sup> This is mainly because of (1) the minimally invasive nature of blood vs bone marrow (BM) analyses, (2) the possibility for more precise quantification of absolute numbers of CTPC than BM minimal residual disease (MRD) resulting from absence of potential hemodilution, and (3) the (nonlinear) correlation observed between CTPC numbers and BM disease burden at diagnosis.<sup>1,3</sup> Recently, we have shown by high-sensitivity next-generation flow (NGF) that CTPC are systematically present in blood of MM at diagnosis, with an adverse prognostic impact for higher counts.<sup>3</sup> These results highlight the relevance of greater levels of disease dissemination via blood in conferring a malignant behavior to MM, suggesting the presence of blood CTPC might be required for subsequent disease progression of treated MM patients.


Based on this hypothesis, here we investigate for the first time the prognostic impact of CTPC by NGF in blood of 137 newly diagnosed MM patients after active treatment outside clinical trials (supplemental Table 1 on the *Blood* Web site), in parallel to BM MRD and serum immunofixation (sIF). Overall, a total of 328 samples were analyzed: 274 paired BM and blood samples, plus 54 follow-up blood specimens. Following the EuroFlow-NGF MM MRD approach,<sup>4</sup> a median (range) of 6 mL (3–14 mL) of blood and 1.8 mL (0.3–5 mL) of BM sample were lysed to (systematically) obtain  $\geq 10^7$  cells per sample. In parallel, sIF was measured by the HYDRAGEL kit (HYDRASYS system, Sebia, Barcelona, Spain).<sup>5</sup> Statistical significance was set at  $P$  values  $< .05$  (supplemental Materials). All studies were approved by the institutional review board.

Following therapy, persistence of CTPC in blood was detected in 26% of MM cases. This represents a 50% higher frequency

than previously reported by conventional flow cytometry (18%–19%),<sup>6–8</sup> reaching rates similar to those found with other high-sensitivity techniques such as allele-specific oligonucleotide polymerase chain reaction (25%–28.8%<sup>9,10</sup>) or next-generation sequencing (31%–34%<sup>2,11</sup> for cell-free DNA and 40%<sup>2</sup> for genomic leukocyte DNA). This translated into even higher differences among patients who reached complete response (CR)/stringent CR (sCR): 17% CTPC<sup>+</sup> cases in our series vs 0%<sup>12,13</sup> to  $< 8\%$ <sup>6,8</sup> in other previous conventional flow cytometry studies (supplemental Table 2).

Despite the greater sensitivity and rate of positivity for CTPC reported here, a significant proportion of our MM cases that were BM MRD<sup>+</sup> or sIF<sup>+</sup> still had undetectable CTPC in (paired) blood samples: 55/137 (40%) and 41/137 (30%), respectively. In contrast, 15/36 (42%) CTPC<sup>+</sup> cases were also sIF<sup>−</sup> (supplemental Table 2). These findings indicate that CTPC is a less sensitive MRD marker in MM than BM MRD, complementary to sIF, in line with previous observations.<sup>1</sup> However, although BM MRD and sIF mainly reflect persistence of resistant tumor<sup>14</sup> and tumor cell–derived immunoglobulins,<sup>15</sup> they fail to provide insight on the ability of these cells to support tumor regrowth and/or dissemination, which ultimately determine disease progression. In contrast, CTPC might not only reflect tumor load but, particularly, the ability of persisting tumor cells to disseminate the disease and support tumor growth and progression at (multiple) distant sites in BM and other tissues, as previously suggested<sup>16</sup> based on their more immature and prominent stem cell-like PC features compared with (paired) BM-derived tumor-plasma cells (TPC).<sup>3</sup>

Despite all of this, every CTPC<sup>+</sup> case in our cohort was BM MRD<sup>+</sup>, suggesting that the presence of blood CTPC after therapy might be a surrogate marker of persistent BM MRD in guiding (eg, avoiding) subsequent (more invasive) BM aspiration



**Figure 1. Prognostic impact of blood CTPC by NGF (vs BM MRD and sIF) on PFS of MM patients according to patient response to therapy.** (A-B) Effect of PB CTPC, (D-E) BM MRD, (H) combination of both parameters, and (G) PB CTPC together with sIF status on PFS is displayed for (A, D, G) the entire MM cohort and (B, E, H) for sCR and CR patients, respectively. PFS curves of MM patients grouped according to (C) their sequential PB CTPC ( $-/-$  or  $+/-$  vs  $-/+$  and  $+/+$ ), (F) sIF status, or (I) a combination of both, are shown. Overall, CTPC $^-$  and MRD $^-$  was defined as the absence of TPC in PB or BM by NGF, respectively, with a limit of detection of  $<2 \times 10^{-6}$ . CR, complete response; NR, not reached; PB, peripheral blood.

procedures, particularly among sCR/CR patients. In contrast, a significant fraction of our CTPC $^-$  cases were BM MRD $^+$  and/or sIF $^+$ , supporting the notion that MM is a BM disease with greater levels of infiltration by (usually) functional PC in BM vs PB. Prolonged half-life ( $\sim 23$  days) and complete clearance ( $\sim 29$  weeks) of the M-protein for the most prevalent immunoglobulin G subclass,<sup>17</sup> in addition to persistence of extramedullary disease<sup>18</sup> and/or the administration of monoclonal antibody-therapy (eg, daratumumab)<sup>19</sup> for MM patients, might also explain sIF positivity in at least a subset of BM MRD $^-$ /sIF $^+$  cases. Additionally, poor BM sample quality (eg, from hemodilution) might also play a role because abnormally low ( $\leq 0.002\%$ )<sup>4</sup> mast cell counts were detected here in 5/10 BM MRD $^-$ /sIF $^+$  cases. In contrast, sIF negativity among 4 of our non-sCR/CR patients could be related to the appearance/persistence of plasmacytomas<sup>18</sup> (2/4 cases),

and high free light chain ratio levels ( $>500$ ) without measurable M-component in serum and urine<sup>18</sup> (1/4 cases), together with a non-secretory TPC<sup>15</sup> detectable here in another MM patient.

From the prognostic point of view, our results based on real-world MM show for the first time that the absence vs presence of blood CTPC by NGF is a new powerful independent prognostic marker for progression-free survival (PFS) measured from the time of BM-MRD/CTPC assessment both among the entire MM patient cohort (hazard ratio [HR], 5.1; 95% confidence interval [CI], 2.9-8.9;  $P < .0001$ ) (Figure 1A) and within sCR/CR cases (HR, 7.4; 95% CI, 3.0-18.2;  $P < .0001$ ; Figure 1B), complementary to currently available prognostic tools such as sIF and BM MRD, respectively (Table 1), and regardless of the treatment phase BM-MRD/CTPC being assessed (supplemental Figure 1).

**Table 1. Multivariate analysis of prognostic factors For PFS In MM**

	Univariate analysis		Multivariate analysis		
	Median PFS (mo)	P	HR	(95% CI)	P
<b>Prognostic factors for entire MM series</b>					
Age					
<65 y	28	.3	—	—	—
≥65 y	36				
Cytogenetic profile by FISH					
Standard-risk	36	.07	—	—	—
High-risk	16				
Serum IF					
Negative	41	.001	—	—	—
Positive	18		2.4	(1.3-4.4)	.004
BM MRD status by NGF					
Negative	46	<.0001	—	—	—
Positive	25				
PB CTPC status by NGF					
Negative	46	<.0001	—	—	—
Positive	9		5.1	(2.9-8.9)	<.0001
<b>Prognostic factors for sCR/CR cases</b>					
Age					
<65 y	50	.5	—	—	—
≥65 y	41				
Cytogenetic profile by FISH					
Standard-risk	50	.09	—	—	—
High-risk	28				
BM MRD status by NGF					
Negative	50	<.0001	—	—	—
Positive	25		6.1	(1.5-24.4)	.01
PB CTPC status by NGF					
Negative	46	<.0001	—	—	—
Positive	9		7.4	(3.0-18.2)	<.0001

High-risk cytogenetics was defined as presence at diagnosis of t(4;14); t(11;14); t(14;16); 1q amplification, deletion 13q, and/or deletion 17p. Standard-risk cytogenetics includes all other cases. (Data available in 96/137 cases.)

FISH, fluorescent in situ hybridization; IF, immunofixation.

Based on those covariables that showed a (statistically) significant effect on PFS in multivariate analysis (Table 1), a prognostic score was built that allowed identification of a subgroup of blood CTPC<sup>+</sup> MM patients with a very poor outcome (score 2 in the risk stratification models proposed here) with PFS rates at 2 years of only 1% for the entire patient cohort (Figure 1G) and of 33% for sCR/CR MM patients (Figure 1H), respectively.

These results, together with the demonstration that CTPC are systematically detected in blood of MM at diagnosis<sup>3</sup> and at relapse,<sup>13</sup> suggest that detection of blood CTPC rather than a surrogate marker of response is a strongly reliable predictor of impending (early) disease progression<sup>9</sup> (Figure 1A-B). In contrast, BM MRD would be a better predictor of persistent disease (Figures 1D-E) and longer term prognosis of MM undergoing different therapies, as recurrently shown in the literature in the settings of clinical trials, both for conventional<sup>20-22</sup> and for high-sensitivity NGF<sup>4,23</sup> and next-generation sequencing<sup>24</sup> approaches. However, frequent BM sampling is hampered by the invasive nature of BM aspiration procedures,<sup>1</sup> whereas more frequent follow-up of CTPC in blood is feasible. Thus, sequential monitoring of blood CTPC was performed in a subset of 54 cases in parallel

to sIF. Our results showed that MM patients who were persistently CTPC<sup>-</sup> (CTPC<sup>-/-</sup>) or that became CTPC<sup>-</sup> after being CTPC<sup>+</sup> (CTPC<sup>+/-</sup>) showed a significantly better outcome than cases with a blood CTPC<sup>+</sup> result in the last follow-up study (CTPC<sup>+/+</sup> or <sup>-/+</sup>) (Figure 1C), independent of sIF status (Figure 1F, I). However, this should be confirmed in larger series of patients with longer monitoring because the limited number of sIF<sup>+/+</sup> or <sup>-/+</sup> (n = 7) cases was observed for a paradoxically (slightly) better outcome vs the sIF<sup>-/-</sup> or <sup>+/-</sup> (n = 34) MM showing no CTPC in the last follow-up study (ie, CTPC<sup>-/-</sup> or <sup>+/-</sup> cases) (Figure 1I). In spite of that, the former findings suggest that blood CTPC might provide additional relevant prognostic information to single time-point BM MRD assessment in predicting for longer term outcome in patients that either (persistently) remain or turn CTPC<sup>-</sup> in sequential follow-up studies, in line with previous reports.<sup>9,25</sup>

In summary, we show here that blood CTPC is a novel independent prognostic marker for PFS in real-world MM prone to more frequent monitoring, which provides early indication of impending disease progression, regardless of BM MRD and sIF status. These results suggest that presence of blood CTPC

of MM after therapy probably reflects a unique distinct tumor biology (eg, tumor dissemination capacity) at a given time point after therapy with important clinical consequences. Further studies in larger series of MM patients outside and inside clinical trials are required to confirm our findings.

## Acknowledgments

The authors thank Sergio Matarraz and Lourdes Martín-Martín for their support on statistical analysis.

This work has been supported by the International Myeloma Foundation-Black Swan Research Initiative and the EuroFlow Consortium; Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC; Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid, Spain, and FONDOS Europeo de Desarrollo Regional) grants CB16/12/00400 (L.S.-F., J.F.-M., A.C.-M., and A.O.), CB16/12/00233 (N.P., O.G.-S., M.D.-C., M.G. and M.-V.M.), CB16/12/00369 and CB16/12/00489 (B.P. and J.S.M.); grant SA079U14 from the Consejería de Educación, Junta de Castilla y León, Valladolid, Spain; and grant DTS15/00119 from the Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid, Spain; by the Research Foundation of the State of Rio de Janeiro, Rio de Janeiro, Brazil (grant E26/110.105/2014) and Conselho Nacional de Desenvolvimento Científico e Tecnológico-CNPQ of Brazil (grants 303765/2018-6 and 409440/2016-7).

The EuroFlow Consortium is an independent scientific consortium that aims at innovation and standardization of diagnostic flow cytometry. All consortium members that contributed are listed as authors. All acquired knowledge and experience within EuroFlow is shared with the scientific and diagnostic community after protection of the relevant Intellectual Property; for example, by filing patents. The involved patents are owned by the EuroFlow Consortium and licensed to companies, including Cytognos SL (Salamanca, Spain), Becton/Dickinson Biosciences (San José, CA), and Immunostep SL (Salamanca, Spain). The revenues of the patents are exclusively used for EuroFlow Consortium activities, such as for covering (in part) the costs of the Consortium meetings, the EuroFlow Educational Workshops, and the purchase of custom-made reagents for collective experiments. J.F.-M., J.J.M.v.D., and A.O. are part of the inventors on the EuroFlow-owned patent PCT/NL/2013/050420; US 62/072 498 (Methods, reagents and kits for detecting minimal residual disease). This patent is licensed to Cytognos, which pays royalties to the EuroFlow Consortium.

## Authorship

Contribution: L.S.-F., T.C.S., R.P., A.C.-M., and O.G.S. performed experiments; L.S.-F. and J.F.M. analyzed results; N.P., M.D.-C., R.J.P.d.M., L.G.-M., J.M.A.-A., A.G.-M., C.A.-F., J.L., A.B.-G., A.M., E.S.d.C. and M.G. contributed to the data collection and performed patients management; L.S.-F., J.F.-M., B.P., J.S.M., M.V.M., B.D., J.J.M.v.D., and A.O. designed the research; and L.S.-F., J.F.-M. and A.O. wrote the paper.

Conflict-of-interest disclosure: M.-V.M. declares honoraria for lectures and advisory boards from Janssen, Celgene, Amgen, Takeda, Abbvie, GSK, Adaptive, EDO-Mundipharma, and Pharmamar. The remaining authors declare no competing financial interests.

ORCID profiles: L.S.F., 0000-0002-9275-7793; J.F.M., 0000-0002-1119-4387; R.P., 0000-0003-3608-8254; M.D.C., 0000-0002-1467-6779; J.S.M., 0000-0002-9183-4857; E.S.da.C., 0000-0002-5340-5816; A.O., 0000-0002-0007-7230.

Correspondence: Alberto Orfao, Centro de Investigación del Cáncer (CSIC-USAL), Avenida Universidad de Coimbra S/N, Campus Miguel de Unamuno, Salamanca 37007, Spain; e-mail: orfao@usal.es.

## Footnotes

For original data, please contact orfao@usal.es.

The online version of this article contains a data supplement.

## Appendix: study group members

The members of the EuroFlow Consortium are: J.J.M.v.D., W. M. Bitter, B. R. Lubbers, A. S. M. van der Meij, C. I. Teodosio, M. Zlei, A. J. van der Sluijs-Gelling, M. van der Burg (Leiden University Medical Center); V. H. J. van der Velden, A. W. Langerak, J. te Marvelde, J. Schilperoord-Vermeulen, A. Blijkerk, K. C. Heezen (Erasmus MC); A.O., J. Almeida, M. B. Vidriales, J.F.-M., M. Pérez-Andrés, S. Matarraz, E. Blanco, L. Martín, Q. Lecrevisse, J. J. Pérez-Morán, N. Puig (University of Salamanca); A. Medina Almeida, M. Gomes da Silva, T. Faria (Instituto Português de Oncologia); M. Brüggemann, M. Ritgen, M. Szczepanowski, S. Kohlscheen, A. Steinert, E. Harbst, J. Finke (University of Schleswig-Holstein); V. Asnafi, L. Lhermitte, E. Duroyon (Hôpital Necker-Enfants Malades); J. Trka, O. Hrusak, T. Kalina, E. Mejstrikova, M. Novakova, D. Thumer, V. Kanderova (Charles University); T. Szczepanski, L. Sędek, J. Balsa, L. Slota, J. Kulis (Medical University of Silesia); C. E. Pedreira, E. Sobral da Costa (Federal University of Rio de Janeiro); S. Nierkens, A. de Jong, A. de Koning (Dutch Childhood Oncology Group); M. Lima, A. H. Santos (Centro Hospitalar do Porto/University of Porto); S. Böttcher, S. Lange, R. Engelmann, D. Paape, C. Machka (Universitätmedizin Rostock); G. Gaipa, C. Burracchi, C. Bugarin (Università di Milano); E. Lopez-Granados, L. del Pino Molina (University Hospital La Paz-IdiPAZ); M. Vilkoa, J. Nechvatalova (St Anne's Faculty Hospital); M. Roussel (University of Rennes); L. Campos-Guyotat, C. Aanei (CHU de Saint-Etienne); J.S.M., B.P., L. Burgos (Universidad de Navarra); N. Villamor-Casas, L. Magnano (Hospital Clínic de Barcelona); J. Philippé, C. Bonroy, B. Denys, A. Willems, P. Brueghe, J. de Wolf (University Hospital Ghent); A. E. Sousa, S. L. Silva (University of Lisbon); P. Fernandez, D. Morf (Kantonsspital Aarau).

## REFERENCES

1. Waldschmidt JM, Anand P, Knoechel B, Lohr JG. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. *Semin Hematol*. 2018;55(1):33-37.
2. Oberle A, Brandt A, Voigtlaender M, et al. Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. *Haematologica*. 2017;102(6):1105-1111.
3. Sanoja-Flores L, Flores-Montero J, Garcés JJ, et al; EuroFlow consortium. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). *Blood Cancer J*. 2018;8(12):117.
4. Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. *Leukemia*. 2017;31(10):2094-2103.
5. Bossuyt X, Bogaerts A, Schiettekatte G, Blanckaert N. Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system. *Clin Chem*. 1998;44(5):944-949.
6. Chakraborty R, Muchtar E, Kumar SK, et al. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. *Blood Cancer J*. 2016;6(12):e512.
7. Moor I, Bacher VU, Jeker B, et al. Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma. *Bone Marrow Transplant*. 2018;53(12):1599-1602.
8. Cowan AJ, Stevenson PA, Libby EN, et al. Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy. *Biol Blood Marrow Transplant*. 2018;24(7):1386-1391.
9. Korthals M, Sehnke N, Kronenwett R, et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma. *Biol Blood Marrow Transplant*. 2013;19(7):1109-1115.
10. Huhn S, Weinhold N, Nickel J, et al. Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. *Bone Marrow Transplant*. 2017;52(8):1194-1198.
11. Mazzotti C, Buisson L, Maheo S, et al. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. *Blood Adv*. 2018;2(21):2811-2813.

12. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. *Br J Haematol*. 1997;97(1):46-55.
13. Gonsalves WI, Morice WG, Rajkumar V, et al. Quantification of clonal circulating plasma cells in relapsed multiple myeloma. *Br J Haematol*. 2014;167(4):500-505.
14. Paiva B, Corchete LA, Vidriales M-B, et al; Spanish Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Groups. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. *Blood*. 2016;127(15):1896-1906.
15. Dispenzieri A, Kyle R, Merlini G, et al; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*. 2009;23(2):215-224.
16. Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. *Blood*. 2012;120(1):20-30.
17. Drayson M, Morgan G, Jackson G, et al. Prospective study of serum FLC and other M-protein assays: when and how to measure response? *Clin Lymphoma Myeloma*. 2012;9(Suppl 1):S56.
18. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol*. 2016;17(8):e328-e346.
19. Rosenberg AS, Bainbridge S, Pahwa R, Jialal I. Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay. *Clin Biochem*. 2016;49(15):1202-1204.
20. Paiva B, Vidriales MB, Cerveró J, et al; GEM (Grupo Español de MM)/ PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. *Blood*. 2008; 112(10):4017-4023.
21. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. *J Clin Oncol*. 2013;31(20):2540-2547.
22. Lahuerta J-J, Paiva B, Vidriales M-B, et al; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. *J Clin Oncol*. 2017;35(25):2900-2910.
23. Paiva B, Puig N, Cedena MT, et al. Impact of next-generation flow (NGF) minimal residual disease (MRD) monitoring in multiple myeloma (MM): results from the Pethema/GEM2012 trial. *Blood*. 2017;130(Suppl 1):905.
24. Martínez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. *Blood*. 2014;123(20):3073-3079.
25. Chakraborty R, Mughtar E, Kumar SK, et al. Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. *Haematologica*. 2017; 102(8):1439-1445.

DOI 10.1182/blood.2019002610

© 2019 by The American Society of Hematology

## TO THE EDITOR:

# Clinical utility of targeted next-generation sequencing–based screening of peripheral blood in the evaluation of cytopenias

Vignesh Shanmugam,<sup>1</sup> Aric Parnes,<sup>2</sup> Rajeshwari Kalyanaraman,<sup>3</sup> Elizabeth A. Morgan,<sup>1,\*</sup> and Annette S. Kim<sup>1,\*</sup>

<sup>1</sup>Department of Pathology, <sup>2</sup>Division of Hematology, and <sup>3</sup>Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA

One of the most common reasons for hematology consultation is the evaluation of cytopenia(s). The workup of patients who present with cytopenia(s) can be extensive, given the wide differential diagnosis.<sup>1</sup> Although only a minority of patients are ultimately diagnosed with a hematologic malignancy, a key entity to exclude in this differential is myelodysplastic syndrome (MDS),<sup>2</sup> which requires bone marrow morphology and cytogenetics for diagnosis. There is a clinical need for the development of minimally invasive ancillary tests to enhance conventional hematologic workup (eg, complete blood count with differential, B12/folate testing, iron-related studies, and serum protein electrophoresis) in the identification of patients who are at a low risk of having an underlying hematologic malignancy as the cause of cytopenia(s), thereby avoiding a costly and invasive bone marrow biopsy (BMBx).

Mutation profiling of peripheral blood (PB) using next-generation sequencing (NGS) is an attractive solution to this problem because of its potential application as a minimally invasive screen. Recent large-scale genome-sequencing studies using bone marrow samples have demonstrated that most cases of MDS and other related neoplasms, such as acute myeloid leukemia and

myelodysplastic/myeloproliferative neoplasm overlap syndromes, harbor pathogenic somatic mutations in diverse myeloid cancer driver genes.<sup>2-6</sup> Moreover, some or all of these mutations can be detected in PB granulocytes in most patients with MDS and related neoplasms (Phillip D. Michaels, Dahai Wang, A.S.K., manuscript in preparation).<sup>7,8</sup>

Despite these advances and the widespread use of NGS testing, there are limited data on the clinical use of NGS testing in the early evaluation of patients with cytopenia(s). We hypothesize that targeted PB NGS using a myeloid cancer gene panel can be a valuable minimally invasive, ancillary tool in identifying patients with an underlying myeloid neoplasm as the cause of cytopenia(s). Herein, we report the clinical utility of PB screening by targeted NGS testing in a large institutional cohort of patients with cytopenia(s).

After institutional review board approval, we retrospectively identified all patients presenting with PB cytopenia(s) over a 30-month period (January 2015 through June 2017) to the Hematology Clinic at the Dana-Farber/Brigham and Women's